Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Conditions
Interventions
Intervention1: Arm A [NACT + CTRT]: Patients will receive induction chemotherapy in the form of Paclitaxel at 80mg/m2 and Carboplatin at AUC2 weekly for 6 weeks. Following 2-4 weeks of IC, patients wi
Sponsors
Institutional Intramural Funds
Eligibility
Inclusion criteria
Inclusion criteria: 1 Histologically proven invasive cancer of the uterine cervix squamous cell carcinoma adenocarcinoma or adeno-squamous carcinoma 2 FIGO 2018 stages IIB to IVA patients after clinical examination and imaging 3 ECOG performance status 0 to 1 4 Patient fit for curative intent treatment 5 Those who provide willingness to consent for participation in trial and follow up
Exclusion criteria
Exclusion criteria: 1 Patients with recurrent cervical cancers 2 Previous history of abdominal or pelvic radiation 3 Previous history of hysterectomy or major abdominopelvic surgery 4 History of connective tissue disorders 5 Patients with contraindications to undergo MR imaging like metallic prosthesis severe claustrophobia 6 Medical or psychological illness precluding treatment protocol including renal or hepatic dysfunction significant cardiac comorbidities which may preclude delivery of adequate doses of chemotherapy 7. Pregnant and breast-feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Free SurvivalTimepoint: 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints with include 3 years OS and 3 years Distant Metastasis Free survival Patterns of Failure Quality of life assessment based on EORTC QLQ C30 and and EORTC QLQ CX24 questionnaire Acute and Late toxicities with CTCAE v5 Cost benefit analysis and compliance to full treatmentTimepoint: 3 years | — |
Countries
India
Contacts
Public ContactDr Abhishek Shinghal
MPMMCC and HBCH Tata Memorial Centre Varanasi
Outcome results
None listed